147 related articles for article (PubMed ID: 15381110)
1. Human kallikrein 13 involvement in extracellular matrix degradation.
Kapadia C; Ghosh MC; Grass L; Diamandis EP
Biochem Biophys Res Commun; 2004 Oct; 323(3):1084-90. PubMed ID: 15381110
[TBL] [Abstract][Full Text] [Related]
2. The extracellular matrix protein fibronectin is a substrate for kallikrein 7.
Ramani VC; Haun RS
Biochem Biophys Res Commun; 2008 May; 369(4):1169-73. PubMed ID: 18343220
[TBL] [Abstract][Full Text] [Related]
3. Complex formation between human kallikrein 13 and serum protease inhibitors.
Kapadia C; Yousef GM; Mellati AA; Magklara A; Wasney GA; Diamandis EP
Clin Chim Acta; 2004 Jan; 339(1-2):157-67. PubMed ID: 14687906
[TBL] [Abstract][Full Text] [Related]
4. Human kallikrein 4: enzymatic activity, inhibition, and degradation of extracellular matrix proteins.
Obiezu CV; Michael IP; Levesque MA; Diamandis EP
Biol Chem; 2006 Jun; 387(6):749-59. PubMed ID: 16800736
[TBL] [Abstract][Full Text] [Related]
5. Human kallikrein 13 protein in ovarian cancer cytosols: a new favorable prognostic marker.
Scorilas A; Borgoño CA; Harbeck N; Dorn J; Schmalfeldt B; Schmitt M; Diamandis EP
J Clin Oncol; 2004 Feb; 22(4):678-85. PubMed ID: 14966091
[TBL] [Abstract][Full Text] [Related]
6. Biochemical characterization of human kallikrein 8 and its possible involvement in the degradation of extracellular matrix proteins.
Rajapakse S; Ogiwara K; Takano N; Moriyama A; Takahashi T
FEBS Lett; 2005 Dec; 579(30):6879-84. PubMed ID: 16337200
[TBL] [Abstract][Full Text] [Related]
7. Human kallikrein 5: a potential novel serum biomarker for breast and ovarian cancer.
Yousef GM; Polymeris ME; Grass L; Soosaipillai A; Chan PC; Scorilas A; Borgoño C; Harbeck N; Schmalfeldt B; Dorn J; Schmitt M; Diamandis EP
Cancer Res; 2003 Jul; 63(14):3958-65. PubMed ID: 12873991
[TBL] [Abstract][Full Text] [Related]
8. Human kallikrein 13: production and purification of recombinant protein and monoclonal and polyclonal antibodies, and development of a sensitive and specific immunofluorometric assay.
Kapadia C; Chang A; Sotiropoulou G; Yousef GM; Grass L; Soosaipillai A; Xing X; Howarth DH; Diamandis EP
Clin Chem; 2003 Jan; 49(1):77-86. PubMed ID: 12507963
[TBL] [Abstract][Full Text] [Related]
9. Kallikrein 7 enhances pancreatic cancer cell invasion by shedding E-cadherin.
Johnson SK; Ramani VC; Hennings L; Haun RS
Cancer; 2007 May; 109(9):1811-20. PubMed ID: 17354228
[TBL] [Abstract][Full Text] [Related]
10. Characterization of mouse glandular kallikrein 24 expressed in testicular Leydig cells.
Matsui H; Takano N; Takahashi T
Int J Biochem Cell Biol; 2005 Nov; 37(11):2333-43. PubMed ID: 15985384
[TBL] [Abstract][Full Text] [Related]
11. Human kallikrein 14: a new potential biomarker for ovarian and breast cancer.
Borgoño CA; Grass L; Soosaipillai A; Yousef GM; Petraki CD; Howarth DH; Fracchioli S; Katsaros D; Diamandis EP
Cancer Res; 2003 Dec; 63(24):9032-41. PubMed ID: 14695222
[TBL] [Abstract][Full Text] [Related]
12. Human kallikrein 6 degrades extracellular matrix proteins and may enhance the metastatic potential of tumour cells.
Ghosh MC; Grass L; Soosaipillai A; Sotiropoulou G; Diamandis EP
Tumour Biol; 2004; 25(4):193-9. PubMed ID: 15557757
[TBL] [Abstract][Full Text] [Related]
13. Human tissue kallikrein gene family: applications in cancer.
Obiezu CV; Diamandis EP
Cancer Lett; 2005 Jun; 224(1):1-22. PubMed ID: 15911097
[TBL] [Abstract][Full Text] [Related]
14. Matrix metalloproteinase-2: mechanism and regulation of NF-kappaB-mediated activation and its role in cell motility and ECM-invasion.
Philip S; Bulbule A; Kundu GC
Glycoconj J; 2004; 21(8-9):429-41. PubMed ID: 15750784
[TBL] [Abstract][Full Text] [Related]
15. Tumor-associated trypsin participates in cancer cell-mediated degradation of extracellular matrix.
Koivunen E; Ristimäki A; Itkonen O; Osman S; Vuento M; Stenman UH
Cancer Res; 1991 Apr; 51(8):2107-12. PubMed ID: 2009530
[TBL] [Abstract][Full Text] [Related]
16. Human kallikrein 11: a new biomarker of prostate and ovarian carcinoma.
Diamandis EP; Okui A; Mitsui S; Luo LY; Soosaipillai A; Grass L; Nakamura T; Howarth DJ; Yamaguchi N
Cancer Res; 2002 Jan; 62(1):295-300. PubMed ID: 11782391
[TBL] [Abstract][Full Text] [Related]
17. The serine protease inhibitor protease nexin-1 controls mammary cancer metastasis through LRP-1-mediated MMP-9 expression.
Fayard B; Bianchi F; Dey J; Moreno E; Djaffer S; Hynes NE; Monard D
Cancer Res; 2009 Jul; 69(14):5690-8. PubMed ID: 19584287
[TBL] [Abstract][Full Text] [Related]
18. Enzymatic profiling of human kallikrein 14 using phage-display substrate technology.
Felber LM; Borgoño CA; Cloutier SM; Kündig C; Kishi T; Ribeiro Chagas J; Jichlinski P; Gygi CM; Leisinger HJ; Diamandis EP; Deperthes D
Biol Chem; 2005 Mar; 386(3):291-8. PubMed ID: 15843175
[TBL] [Abstract][Full Text] [Related]
19. Enhanced in vitro invasiveness of ovarian cancer cells through up-regulation of VEGF and induction of MMP-2.
Zhang A; Meng L; Wang Q; Xi L; Chen G; Wang S; Zhou J; Lu Y; Ma D
Oncol Rep; 2006 Apr; 15(4):831-6. PubMed ID: 16525667
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of matrix metalloproteinase activity and growth of gastric adenocarcinoma cells by an angiotensin converting enzyme inhibitor in in vitro and murine models.
Williams RN; Parsons SL; Morris TM; Rowlands BJ; Watson SA
Eur J Surg Oncol; 2005 Nov; 31(9):1042-50. PubMed ID: 15993560
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
